Iteos Therapeutics Inc

NASDAQ ITOS

Data sourced from

and

Download Data

Iteos Therapeutics Inc Operating Cash Flow Per Share for the quarter ending March 31, 2024: -0.90

Iteos Therapeutics Inc Operating Cash Flow Per Share is -0.90 for the quarter ending March 31, 2024, a -21.58% change year over year. Operating cash flow per share represents the amount of cash generated from a company's core operations per outstanding share. It is calculated by dividing the operating cash flow by the weighted average number of basic shares outstanding. This metric provides insights into the company's ability to generate cash flow from its day-to-day operations on a per-share basis. It is useful for evaluating the company's cash flow generation and comparing it with other companies on a per-share basis.

Iteos Therapeutics Inc Operating Cash Flow Per Share for the quarter ending March 31, 2023 was -0.74, a -18.13% change year over year.
Iteos Therapeutics Inc Operating Cash Flow Per Share for the quarter ending March 31, 2022 was -0.63, a -49.31% change year over year.
Iteos Therapeutics Inc Operating Cash Flow Per Share for the quarter ending March 31, 2021 was -0.42, a -2,668.69% change year over year.
Iteos Therapeutics Inc Operating Cash Flow Per Share for the quarter ending March 31, 2020 was 0.02, a 103.38% change year over year.

NASDAQ: ITOS

Iteos Therapeutics Inc

CEO	Dr. Michel Detheux Ph.D.
IPO Date	July 24, 2020
Location	United States
Headquarters	321 Arsenal Street, Cambridge, MA, United States, 02472-5710
Employees	157
Sector	Healthcare
Industry	Biotechnology

Description

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc"R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonists that is in Phase 1/2a clinical trials to overcome the specific adenosine-mediated immunosuppression found in tumor microenvironment; and EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to inhibit the immunosuppressive activity of adenosine and restore immune cell proliferation is in Phase 1 clinical trials. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

Key trends